Mildronate injection 0,5 g/5 ml (meldonium) Grindex


Improves Oxygen Delivery to Cells
Excellent for Sportsmen to Improve Stamina
Protects Cells from Intoxication
Improves Energy Levels and Faster Physical Recovery
Treat Chronic Heart Failure and Cerebral Strokes
Abstinence Syndrome

SKU: 2 Category:



In cardiovascular diseases, as a part of complex therapy, the drug is prescribed in a dose of 0.5-1 g per day intravenously (5-10 ml of injection for 500 mg / 5 ml), 1-2 times a day. The course of treatment is 4-6 weeks. When cerebral circulation is disturbed in the acute phase, the drug is administered iv 500 mg once a day for 10 days, then go on to take the drug inside (in a suitable dosage form – 0.5-1 g per day). The general course of therapy is 4-6 weeks. In vascular pathology and dystrophic retinal diseases, Mildronate is injected parabulbar by 0.5 ml of an injection solution with a concentration of 500 mg / 5 ml for 10 days. With mental and physical exertion appoint IV in 500 mg once a day. The course of treatment is 10-14 days. If necessary, the therapy is repeated after 2-3 weeks. In chronic alcoholism, the drug is administered IV for 500 mg twice a day. The course of treatment is 7-10 days. Side effect tachycardia; changes in blood pressure; psychomotor agitation; headache; dyspeptic symptoms; allergic reactions (redness of the skin, rashes or rashes, itching, swelling); general weakness; edema. Contraindications increased intracranial pressure (including with violation of venous outflow, intracranial tumors); children and adolescents under 18; hypersensitivity to the drug. Application in pregnancy and lactation The safety of Mildronate in pregnancy is not proven. To avoid possible adverse effects on the fetus, the drug should not be administered during pregnancy. It is not known whether the drug is excreted in breast milk. If you need to use Mildronate during lactation, breastfeeding should be discontinued. Special instructions Patients with chronic liver and kidney disease should be careful with prolonged use of the drug. If you need a long (more than a month) use of the drug should consult with a specialist. Many years of experience in the treatment of acute myocardial infarction and unstable angina in cardiac units shows that Mildronate is not a first-line drug in acute coronary syndrome. Use in pediatrics In children and adolescents under the age of 18 years, the effectiveness and safety of Mildronate in the form of capsules and solution for injection is not established. Influence on the ability to drive vehicles and manage mechanisms Data on the adverse effects of Mildronate on the rate of psychomotor reaction is not available. Drug Interactions When combined, Mildronate enhances the effect of antianginal drugs, some antihypertensive drugs, cardiac glycosides. Mildronate can be combined with antianginal drugs, anticoagulants and antiaggregants, antiarrhythmics, diuretics, bronchodilators. When combined with Mildronate, nitroglycerin, nifedipine, alpha-adrenoblockers, antihypertensive drugs and peripheral vasodilators may develop moderate tachycardia, arterial hypotension (caution should be exercised when using this combination). Analogues of the drug Mildronate Structural analogues of the active substance: 3- (2,2,2-Trimethylhydrazinium) propionate dihydrate; Vazomag; Idrinol; Cardion; Medatern; Meldonius; Meldonius-Eskom; Meldonium dihydrate; Melfor; Midolat; Trimethylhydrazinium propionate dihydrate